Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

The obesity treatment space has been generating plenty of headlines – and sales – over the past few years. GLP-1 receptor ...

The cross-asset backdrop is classic late-cycle: softer yields, a weaker dollar and bifurcated risk appetite. The U.S. Dollar Index (DXY) dropped roughly 0.6% to around 98.24, its lowest reading since ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Some patients dropped out of the trial early because they had lost so much weight.

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

FDA-approved weight loss medications include injections (Wegovy®, Zepbound®, etc.) and pills, like Qsymia® and Xenical®. Most ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Dec 12 () - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...